查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133469

吉西他濱 HCL-2022-2029 的全球市場

Global Gemcitabine HCL Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

Gemcitabine HCL 的市場增長受到多種因素的推動，例如老年人口的增加、癌症疾病的增加、技術進步以及改善治療的研究工作。

癌症疾病的流行預計將推動市場增長

由於乳腺癌和胰腺癌的增加，全球對鹽酸吉西他濱的需求正在增加。根據世界衛生組織 (WHO) 的數據，癌症是全球主要的死亡原因。 2020年的死亡人數約為1000萬，據說六分之一的患者將死於癌症。最常見的癌症是乳腺癌、肺癌、結腸癌、直腸癌和前列腺癌。大約三分之一的癌症死亡是由高水平的肥胖、飲酒、吸煙、水果和蔬菜攝入量低以及缺乏運動引起的。根據世界衛生組織2022年2月的數據，據說到2020年，將有226萬乳腺癌病例，221萬肺癌病例，120萬皮膚癌病例，193萬大腸癌病例，我來了。此外，每年有 400,000 名兒童患上癌症。宮頸癌是最常見的癌症。癌症疾病的發病率隨著年齡的增長而增加，主要是由於某些癌症危險因素隨著年齡的增長而積累。為了治療癌症患者，必須及時診斷癌症。如果早期發現並得到有效治療，許多癌症可以治愈。治療的正確選擇涉及癌症和個體的考慮。鹽酸吉西他濱靜脈注射，屬於一組稱為抗代謝物的藥物，與細胞中的正常物質非常相似。它是細胞週期特異性的。當細胞將這種物質納入其新陳代謝時，它們就無法分裂。它主要通過在 DNA 合成過程中促進癌細胞的程序性細胞死亡來發揮其抗腫瘤作用。具體來說，它通過 G1/S 期邊界抑制細胞進展。這可以防止細胞分裂並預防各種癌症。

鹽酸吉西他濱的副作用阻礙市場增長

但是，鹽酸吉西他濱的副作用包括異常虛弱、食慾不振、尿色深、手臂和肩部疼痛、突然劇烈頭痛、發燒、發冷、身體疼痛、流感症狀、聽力問題、呼吸問題、研究表明胸痛和沈重。這些副作用給患者帶來健康風險，並可能對市場增長產生不利影響。

COVID-19 影響分析

由於這些藥物的抗病毒活性，COVID-19 的出現對全球對這些藥物的需求產生了相當大的影響。為了防止這種新型病毒作為人類病原體傳播，公共衛生專業人員必須診斷感染、遏制其傳播並治療其病因。例如，吉西他濱具有抗病毒活性，鑑於我們在治療隨後的病毒性疾病（如 MERS-CoV 和 SARS-CoV 感染）方面的經驗，有一份可用於治療 COVID-19 感染的藥物清單。鹽酸吉西他濱是一種這樣的核甘類似物抑製劑。作為 SARS-CoV-2 治療劑有效。因此，作為傳染病的治療劑，在市場上的需求量很大。隨著全球感染冠狀病毒的人數增加，全球需求也在增加。例如，根據世界衛生組織 2022 年 9 月的數據報告，全球有 609,848,852 例冠狀病毒確診病例。

另一方面，在大流行期間，交通限制和封鎖使許多患者難以接受正常護理。但是，現在可以住院治療，因為它在 2022 年中期而不是 2021 年逆轉。預計該市場在預測期內也將顯示出良好的增長。

全球鹽酸吉西他濱市場報告將提供對大約 55 多個市場數據表、50 多個圖表和 250 多頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按應用劃分的市場細分
  • 最終用戶的市場細分
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 老年人口增加
      • 癌症發病率增加
    • 限制
    • 鹽酸吉西他濱的副作用
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管機構分析
  • 流行病學

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按應用程序

  • 胰腺癌
  • 非小細胞肺癌
  • 膀胱癌
  • 軟組織肉瘤
  • 轉移性乳腺癌
  • 卵巢癌

第 8 章最終用戶

  • 醫院
  • 居家護理
  • 專業設施
  • 其他

第 9 章分銷渠道

  • 醫院藥房
  • 在線藥店
  • 零售店

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • 禮來公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Teva Pharmaceutical Industries Ltd.
  • Accord-UK Ltd.
  • Pfizer, Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG
  • Dr. Reddy's Laboratories Ltd.
  • Ingenus Pharmaceuticals
  • NuCana Biomed's

第 13 章。Gemcitabine HCL 全球市場-DataM

簡介目錄
Product Code: DMPH5860

Market Overview

Gemcitabine HCL Market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of X% during the forecast period (2022-2029).

Gemcitabine HCL is an FDA-approved drug with antineoplastic activity. It can be taken as a stand-alone or with other drugs. It is used for breast cancer, non-small cell cancer, ovarian cancer, pancreatic cancer, and others. This medication is given to the patient by injection into a vein by healthcare professionals. The dosage is based on the patient's medical condition, body size, and response to treatment.

Market Dynamics

The gemcitabine HCL market growth is driven by several factors, such as an increase in the geriatric population, an increase in cancer diseases, technological advancements, and research activities for improvising the treatment.

The prevalence of cancer disease is expected to drive the market growth

The rise in breast cancer, pancreatic cancer, and many more is increasing the demand for gemcitabine HCL globally. According to the World Health Organization (WHO), cancer is the main cause of death globally. Approximately 10 million deaths in 2020 will be due to cancer, or nearly one in six deaths of patients. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Around one-third of all cancer deaths are due to high body mass index, alcohol consumption, tobacco use, low vegetable, and fruit intake, and lack of physical activity. According to WHO data from February 2022, in 2020, there will be 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.20 million cases of skin cancer, and 1.93 million cases of colon and rectum cancer worldwide. In addition, every year, 400,000 children develop cancer. Cervical cancer is the most common cancer. The incidence of cancer disease increases with age, mostly due to risk factors building up for specific cancers that rise with age. To treat a cancer patient, it is necessary to diagnose cancer on time. Many cancers can be cured if detected early and treated effectively. In the proper selection of treatment, both cancer and the individual are considered for treatment. Gemcitabine HCL is given intravenously and belongs to a family of drugs called antimetabolites, which are very similar to normal substances within the cell. It is cell-cycle specific. When the cells incorporate these substances into the cellular metabolism, they are unable to divide. Mainly, it shows anitumor effects by promoting programmed cell death of cancer cells undergoing DNA synthesis. Specifically it blocks progression of cells through the G1/S-phase boundary. That's how it prevents the division of cells and prevents different cancers.

The side effects of gemcitabine HCL will hamper the growth of the market

However, studies have shown side effects of gemcitabine HCL, such as unusual weakness, loss of appetite, dark urine, pain spreading to the arm or shoulder, sudden severe headache fever, chills, body aches, flu symptoms, hearing problems, breathing problems, and chest pain and heavy feeling. These side effects create health risks among patients, which may adversely affect the market's growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global demand for these drugs due to their antiviral activity. In order to prevent the novel virus from rising into a pandemic human pathogen, it is essential that public health professionals can diagnose the infection, control its spread, and treat its causes. For instance, due to the antiviral activity of gemcitabine, HCL is compiled in the list of drugs with the potential to be used in the treatment of COVID-19 infection based on experience in treating a subsequence of viral diseases such as MERS-CoV and SARS-CoV infection. Gemcitabine hydrochloride is one of the nucleoside analog inhibitors for this purpose. It is valid for the treatment of SARS-CoV-2 treatment. Due to this, the demand is high in the market to treat the infection. As the cases of coronavirus rise worldwide, the demand has increased worldwide. For instance, as per the WHO data report of September 2022, the confirmed cases of coronaviruses are 609,848,852 globally.

On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The pancreas cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pancreatic cancer segment is expected to hold the dominant market share over the period forecast (2022-2029). Pancreatic cancer is one of the cancers with high mortality and has a common survival rate of 6-8%. In recent years, cancer has been proven to be one of the deadliest in the United States, with high morbidity, typically in elderly patients. Nowadays, there exists a large unmet need for drugs and drug delivery vehicles that can provide excellent therapeutic advantages. Substantial interest in Gemcitabine as a combination therapy is gathering among researchers. An increasing body of studies on its pharmacology has propelled the revenue potential of key players in this segment. Furthermore, pancreatic cancer accounts for 8% of male deaths and 8% of female deaths in the United States, according to the American Cancer Society. In the United States, new cancer cases occur in 3% of males and 3% of females. In addition, more than 90% of cases develop in the exocrine tissue of the pancreas, which helps enzymes digest food. The less common endocrine tumors, mainly referred to as pancreatic neuroendocrine tumours (NETs), develop in hormone-producing cells and have a younger median age at diagnosis and better prediction.

Geographical Analysis

North America region holds the largest market share of the global gemcitabine HCL market

North America dominates the market for gemcitabine HCL and is expected to show a similar trend over the forecast period owing to the increased geriatric population, advanced healthcare infrastructure, increased incidences of cancer diseases, and favorable government initiatives. As per the American Cancer Society, Inc., 2022 report, nearly 1.9 million new cases are anticipated to be diagnosed in the U.S. alone, and there are 609,360 cancer deaths in the United States due to cancer. As we increase in age, there is a risk of developing cancer. 80% of the population diagnosed with cancer in the US is 55 years of age or older, and 57% are 65 or older due to certain behaviors such as drinking alcohol, eating habits, smoking, and having excess body weight. In addition, in the United States, it is estimated that 40 out of 100 men and 39 out of 100 women will develop cancer during their life span. With the increased number of cancer cases, there is more demand for gemcitabine HCL in the market to treat different cancers in patients.

Competitive Landscape

The gemcitabine HCL market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord-UK Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Ingenus Pharmaceuticals and NuCana Biomed's among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the gemcitabine HCL market globally.

For instance,

  • In September 2022, NuCana plc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Acelarin (NUC-1031), derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. It is currently evaluated in a Phase III study for the first-line treatment of patients with advanced biliary tract cancer.

Stryker Corporation

Overview:

Eli Lilly and Company is an American pharmaceutical company headquartered in Indiana, founded in 1876, with a presence in 18 countries. The company receives profit from the marketing of its products for various cancer types for which gemcitabine HCL has been approved.

Product Portfolio:

Gemcitabine HCL:

Gemcitabine HCL is an oncology product for various cancer types. It is FDA approved for the treatment of breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and bladder cancer. In addition, it has been studied for its cytotoxic effect in various types of tumour treatment, including esophageal cancer.

The global Gemcitabine HCL market report would provide access to approximately 55+ market data tables, 50+ figures, and in the range of 250 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Application
  • 3.2. Market snippet By End User
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in geriatric population
      • 4.1.1.2. Increase in cancer diseases
    • 4.1.2. Restraints:
    • 4.1.3. Side effects of Gemcitabine HCL
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Pancreas Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-small Cell Lung Cancer
  • 7.4. Bladder Cancer
  • 7.5. Soft-Tissue Sarcoma
  • 7.6. Metastatic Breast Cancer
  • 7.7. Ovarian Cancer

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Homecare
  • 8.4. Specialty Centers
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Eli Lilly and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Teva Pharmaceutical Industries Ltd.
  • 12.3. Accord-UK Ltd.
  • 12.4. Pfizer, Inc.
  • 12.5. Mylan N.V.
  • 12.6. Sun Pharmaceutical Industries Ltd.
  • 12.7. Fresenius Kabi AG
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Ingenus Pharmaceuticals
  • 12.10. NuCana Biomed's

LIST NOT EXHAUSTIVE

13. Global Gemcitabine HCL Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us